Clinical Trials Logo

Rosacea clinical trials

View clinical trials related to Rosacea.

Filter by:

NCT ID: NCT06331533 Completed - Clinical trials for Erythematotelangiectatic Rosacea

Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea

Start date: November 1, 2022
Phase: Phase 4
Study type: Interventional

Investigation of the effectiveness of intradermal botulinum toxin A treatment in the treatment of erythematotelangiectatic rosacea (ETR) using clinical, biophysical, dermatoscopic and videocapillaroscopy.

NCT ID: NCT06312813 Recruiting - Rosacea Clinical Trials

Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea

Start date: February 27, 2024
Phase: Phase 2
Study type: Interventional

Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.

NCT ID: NCT06307288 Enrolling by invitation - Rosacea Clinical Trials

Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea

Start date: October 16, 2023
Phase: Phase 4
Study type: Interventional

Rosacea is a chronic inflammatory skin disease with a complex pathogenesis involving multiple factors. Currently, the treatment of rosacea remains highly challenging. Mast cells, as key participants in the pathogenesis of rosacea, have been shown to alleviate rosacea symptoms with some topical, oral, and injectable mast cell stabilizers in recent years. Tranilast stabilizes mast cells and basophils by acting on their cell membranes and preventing their degranulation. Tranilast has been used in the treatment of various skin disease, such as hypertrophic scars and atopic dermatitis. Minocycline is a first-line treatment for rosacea, and low-dose minocycline treatment (50mg/day) is believed to have anti-inflammatory effects without antibacterial effects, thus minimizing the dysbiosis and bacterial resistance caused by antibiotic use. Therefore, this study aims to investigate the effectiveness and safety of combining mast cell stabilizer tranilast with low-dose minocycline treatment for rosacea, providing new treatment options and insights for rosacea patients.

NCT ID: NCT06282679 Recruiting - Rosacea Clinical Trials

Clinical Observation of Botulinum Toxin A Treatment in the Treatment of Rosacea

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

the goal of this study is to study the clinical efficacy and safety of botox in the treatment of rosacea.

NCT ID: NCT06271135 Completed - Rosacea Clinical Trials

Assessing the Quality of Life of Patients With Rosacea

Start date: May 8, 2017
Phase: N/A
Study type: Interventional

The study population consisted of 160 patients (123 women and 37 men) with rosacea, who agreed to participate in this study. Patients were qualified for the study among people visiting the cosmetic studio in Choroszcz in the period from June 2017 to November 2018, based on the diagnosis of a dermatologist and cosmetologist. The cosmetic intervention was performed using CAPILLARY REPAIR SERUM (30ml). Study participants completed self-reported questionnaire and standardized questionnaires.

NCT ID: NCT06072066 Not yet recruiting - Rosacea Clinical Trials

Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea

Start date: October 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.

NCT ID: NCT06033352 Recruiting - Rosacea Clinical Trials

Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea

KIR
Start date: September 12, 2023
Phase: Phase 2
Study type: Interventional

Rosacea is a frequent chronic inflammatory disease affecting mainly the face but also eyes and scalp. Rosacea is classified into 3 types: erythemato-teleangiectatica, papulopustulosa and phymatosa. Treatments depend on the type and include topical and systemic antibiotics, azelaic acid, topical ivermectin, topical brimonidine, systemic isotretinoin as well as intense pulsed light (IPL) and laser therapies. For treatment of telangiectasia and redness, laser and IPL therapies are the first choice. Vascular lasers, such as pulsed dye lasers (PDL) and potassium-titanyl phosphate (KTP) lasers as well as IPL, have demonstrated good efficacy in reduction of erythema and telangiectasias in patients with rosacea. However, these treatments are expensive and mostly not covered by the health insurance. Therefore, for patients it is important to receive the maximal effect and improvement after each single laser session. Ivermectin is a semi-synthetic derivative of avermectin and has an anti-inflammatory effect as well as an antiparasitic effect on demodex mite. The latter is playing an important pathogenetic role in rosacea. This randomized controlled study aims to compare the effect of KTP laser in combination with ivermectin 1% cream vs KTP laser alone in patients with facial rosacea.

NCT ID: NCT06013371 Recruiting - Clinical trials for Papulopustular Rosacea

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with moderate-to-severe papulopustular rosacea (PPR). Subjects will be randomized 2:1 to receive study drug or placebo. Enrolled subjects will apply topical PF-07038124 0.02% ointment once daily for 8 weeks. They will return for visits at weeks 4, 8, and 12 following study treatment initiation for repeat clinical assessments, medication reviews, tape-strip, blood and urine sample collections, and monitoring for adverse events.

NCT ID: NCT05942248 Recruiting - Acne Clinical Trials

The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis

Start date: June 6, 2023
Phase: N/A
Study type: Interventional

The study is conducted to determine if image-based computer grading can of acne, melasma, rosacea and seborrheic dermatitis correlate well to expert based clinical severity grading.

NCT ID: NCT05861310 Not yet recruiting - Rosacea Clinical Trials

Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy

Start date: May 2023
Phase: Phase 1
Study type: Interventional

Rosacea is a chronic inflammatory disease of the central facial region, which can also occur in the neck and chest regions. Microbes that play a role in rosacea are Demodex folliculorum and Helicobactor pylori. On the skin with rosacea have decreased skin barrier function. This clinical study will compare the effectiveness and safety of metronidazole 1% cream as the main therapy in rosacea patients. Participants who will become research subjects are women and men aged 18-60 years who meet the inclusion criteria. Research subjects were divided into 2 groups. The control group will use placebo cream (without the drug substance) and the comparison group will use metronidazole 1% cream.